Saturday, March 25 I 2:00 PM – 6:10 PM
Sunday, March 26 I 7:00 AM – 10:10 AM
Grand Ballroom BC
Earn up to
Upon completion of this activity, participants should be able to:
Describe HBV/HDV management recommendations/guidelines for new treatments and describe current guidelines for the diagnosis and management of gastrointestinal disorders.
Utilize new therapies and employ an evidence-based approach to the management of gastrointestinal disorders to optimize treatment results for patients with HBV/HDV.
Identify new advances and assess their potential impact on clinical practice.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Chronic Liver Disease Foundation (CLDF). Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this Live Activity for a maximum of 3.75 AMA PRA Category 1 Credits™ on Saturday, March 25, 2023 and 2.75 AMA PRA Category 1 Credits™ on Sunday, March 26, 2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, CLDF staff, and Purdue University College of Pharmacy staff have a relevant financial relationship(s) with ineligible companies to disclose unless listed below.
This activity is jointly provided by the Purdue University College of Pharmacy and the Chronic Liver Disease Foundation.
This activity is supported by an educational grant from Gilead Sciences, Inc.